Variant MAAP Polypeptides for Higher rAAV Production in HEK293 Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant Adeno-Associated Virus (rAAV) virions in sufficient quantities to meet clinical demand are inefficient and challenging.
Innovation Solution
Development of variant membrane-associated accessory polypeptides (MAAP) that enhance the production of rAAV virions by increasing packaging levels in producer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If plasmid DNA transfection into HEK293 cells is used for rAAV manufacturing, then the process is established and commonly used, but the production quantity is insufficient to meet clinical demand
Solution Approach 1:
The patent applies parameter changes by modifying the MAAP protein sequence to create variants with enhanced functionality. Specifically, amino acid substitutions are introduced at positions 60, 63, and 64 (e.g., P60S, D63E, N64T) to optimize packaging efficiency and increase rAAV production quantities while maintaining manufacturing reliability
Solution Approach 2:
The patent creates multiple copies of the MAAP gene in the HEK293 cell system through plasmid transfection. The enhanced MAAP variants are expressed as multiple copies per cell, amplifying the packaging function and thereby increasing overall rAAV production capacity to meet clinical demand
2Productivity
If wild-type MAAP is used in producer cells, then the packaging process functions normally, but packaging levels are insufficient to achieve high rAAV production
Solution Approach 1:
The patent modifies specific amino acid parameters in the MAAP sequence to enhance packaging function. The substitutions at positions 60, 63, and 64 change the protein's interaction properties with viral genomes and capsids, directly increasing packaging levels and making the manufacturing process more efficient
Solution Approach 2:
The enhanced MAAP variants perform their packaging function more effectively without requiring additional external factors. The modified proteins self-optimize the packaging process by improving their intrinsic ability to facilitate genome encapsidation, thereby increasing productivity without complicating the manufacturing procedure
Data Source
AI summary
The present disclosure provides variant membrane-associated accessory polypeptides (MAAP). The present disclosure provides recombinant AAV (rAAV) comprising a nucleotide sequence encoding a variant MAAP of the present disclosure. The present disclosure provides methods producing rAAV virions, using a variant MAAP of the present disclosure.